Disc Medicine (NASDAQ:IRON) Stock Rating Reaffirmed by HC Wainwright

Disc Medicine (NASDAQ:IRON)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $70.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 46.47% from the stock’s current price.

A number of other equities analysts also recently commented on IRON. BMO Capital Markets reissued an “outperform” rating and issued a $70.00 target price (up previously from $50.00) on shares of Disc Medicine in a research note on Monday, June 17th. Wells Fargo & Company started coverage on shares of Disc Medicine in a research note on Thursday, August 22nd. They issued an “overweight” rating and a $75.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Tuesday, May 28th. Finally, Wedbush reissued an “outperform” rating and issued a $57.00 target price on shares of Disc Medicine in a research note on Friday, August 9th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Disc Medicine has an average rating of “Moderate Buy” and a consensus price target of $64.13.

Disc Medicine Stock Down 1.0 %

NASDAQ:IRON opened at $47.79 on Monday. The company has a market cap of $1.18 billion, a P/E ratio of -14.14 and a beta of 0.59. Disc Medicine has a fifty-two week low of $25.60 and a fifty-two week high of $77.60. The firm’s 50 day moving average is $46.95 and its two-hundred day moving average is $43.77.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($1.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.08. Research analysts forecast that Disc Medicine will post -4.19 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Disc Medicine

A number of large investors have recently added to or reduced their stakes in the company. Atlas Venture Life Science Advisors LLC grew its holdings in Disc Medicine by 9.7% during the 2nd quarter. Atlas Venture Life Science Advisors LLC now owns 2,509,456 shares of the company’s stock valued at $113,101,000 after purchasing an additional 222,223 shares in the last quarter. Frazier Life Sciences Management L.P. grew its holdings in Disc Medicine by 123.5% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 1,754,834 shares of the company’s stock worth $79,090,000 after acquiring an additional 969,834 shares in the last quarter. Deerfield Management Company L.P. Series C grew its holdings in Disc Medicine by 53.8% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,023,265 shares of the company’s stock worth $46,119,000 after acquiring an additional 357,730 shares in the last quarter. Perceptive Advisors LLC grew its holdings in Disc Medicine by 14.2% during the 4th quarter. Perceptive Advisors LLC now owns 1,023,045 shares of the company’s stock worth $59,091,000 after acquiring an additional 127,404 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in Disc Medicine by 59.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 944,213 shares of the company’s stock worth $58,788,000 after acquiring an additional 353,382 shares in the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.